Phase 2 Trial Of Induction Chemotherapy Regimen (GEMPOX) Followed By A Single Cycle Of High Dose Chemotherapy (HDC) And Autologous Hematopoietic Stem Cell Rescue (AUHSCR) For Patients With Recurrent Or Progressive Intracranial Germ Cell Tumors

Brief description of study

If you have been diagnosed with recurrent or progressive intracranial germ cell tumors and are exploring treatment options, you may qualify for a clinical trial studying the effects of induction chemotherapy regimen Gemcitabine Paclitaxel and Oxaliplatin (GemPOx) followed by a single cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoietic STEM Cell Rescue (AuHSCR). Purpose The primary goal of the study is to find out how often tumors shrink with at least two and up to four courses of induction chemotherapy with GemPOx regimen in patients with recurrent or progressive intracranial germ cell tumors. The study aims to investigate overall survival and event-free survival (the length of time after primary treatment for a cancer ends that the patient remains free of certain complications) of patients treated on the GemPOx induction regimen followed by the HDC and AuHSCR and also study the feasibility and side effects of HDC and AuHSCR with GemPOx regimen in patients with progressive or recurrent intracranial germ cell tumors.


Clinical Study Identifier: s13-00463
ClinicalTrials.gov Identifier: NCT01270724
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.